How to Start GLP-1 Receptor Agonist Therapy
Begin with the lowest available dose of a long-acting GLP-1 receptor agonist (dulaglutide, liraglutide, or semaglutide) and up-titrate slowly every 1-4 weeks to reduce nausea and vomiting, targeting the doses proven effective in cardiovascular outcome trials. 1, 2
Initial Dosing Strategy
Start low and titrate slowly to minimize gastrointestinal side effects, which occur in 15-20% of patients but typically abate over several weeks to months 1, 2:
- Dulaglutide: Start 0.75 mg weekly, increase to 1.5 mg weekly after 4 weeks
- Liraglutide: Start 0.6 mg daily, increase by 0.6 mg weekly up to 1.8 mg daily
- Semaglutide (injectable): Start 0.25 mg weekly, increase to 0.5 mg after 4 weeks, then 1.0 mg after another 4 weeks
The goal is to reach the doses used in cardiovascular outcome trials that demonstrated MACE reduction 2.
Medication Adjustments Before Starting
If the patient is on insulin, sulfonylureas, or glinides and has well-controlled A1C or frequent hypoglycemia, reduce doses proactively 3:
- Decrease sulfonylurea dose by 50%
- Decrease basal insulin dose by 20%
Discontinue any DPP-4 inhibitor before initiating GLP-1 therapy, as these mechanisms overlap 3.
Patient Education Points
Educate patients about expected effects and warning signs 1, 3:
- Gastrointestinal symptoms (nausea, vomiting, diarrhea) are common initially but usually resolve within weeks
- Monitor blood glucose more closely for the first 4 weeks, especially if on insulin or sulfonylureas
- Discontinue immediately and seek care if symptoms of pancreatitis develop (severe abdominal pain, nausea, vomiting)
- Weight loss of 2-3 kg is typical, though glycemic benefit occurs even without weight loss 4
- Injection site reactions are rare (<1%) 2
Monitoring During Titration
- Instruct closer home glucose monitoring for the first 4 weeks 3
- Monitor renal function, particularly if eGFR is borderline or the patient is on ACE inhibitors/ARBs 1
- Watch for hypoglycemia if on concurrent insulin or secretagogues, even though GLP-1 agonists themselves don't cause hypoglycemia 2
Special Considerations by Renal Function
GLP-1 receptor agonists retain glucose-lowering potency across all levels of kidney function 2:
- eGFR ≥30 mL/min/1.73 m²: No dose adjustment needed for most agents
- eGFR 15-29 mL/min/1.73 m²: Use with caution; dulaglutide, liraglutide, and semaglutide can be used
- eGFR <15 mL/min/1.73 m²: Exenatide and lixisenatide not recommended; other long-acting agents can be used 1, 2
Common Pitfalls to Avoid
Do not titrate too quickly—this is the primary cause of treatment discontinuation due to intolerable nausea 1. The slow titration schedule exists specifically to improve tolerability.
Do not delay gastric emptying considerations—GLP-1 agonists slow gastric emptying, so use caution in patients with gastroparesis or prior gastric/bariatric surgery 1. This effect is usually transient with longer-acting agents.
Do not forget retinal screening—particularly with semaglutide, ensure appropriate eye examinations are current before starting if not done within 12 months, as rapid glucose improvement may worsen diabetic retinopathy 1, 3.
Do not use in patients with personal or family history of medullary thyroid carcinoma or MEN2—this is an absolute contraindication 1, 2.
Preferred Agents
Choose dulaglutide, liraglutide, or semaglutide as these have demonstrated cardiovascular benefit in outcome trials and are preferred agents 2. Liraglutide specifically has an FDA indication to reduce MACE in adults with type 2 diabetes and established cardiovascular disease 4.